Skip to content

Study · Non-randomized trial · 2008

4 results

Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.

Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Nihoyannopoulos P, Kemp M, Hooper J, Rajkumar C

Clinical endocrinology13 Aug 2007Cited by 23 (Europe PMC)

PMID17692108 (opens in a new tab)DOI10.1111/j.1365-2265.2007.02999.x (opens in a new tab)PepBankPUB-17692108
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialMechanism

    In men with prostate cancer, testosterone fell by a mean of 88% from baseline after 6 months of goserelin.

    In plain wordsIn men with prostate cancer, testosterone fell by 88% on average from baseline after 6 months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseTestosterone
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean change in testosterone from baseline
    −88%
    goserelin, baseline to 6 months

    Source sentences

    Summary
    Mean changes in testosterone and oestradiol, respectively, from baseline to 6 months were -88% and -46% with goserelin, +50% and +44% with bicalutamide, and -1% and -9% for the 'no-treatment' group.
    1 context sentence
    Summary · context
    Forty-three men (mean age 70.7 +/- 6.2 years) with prostate cancer were randomized to goserelin (an LH-releasing hormone analogue) or bicalutamide (an androgen-receptor blocker) for 6 months; 20 men with a history of prostate cancer on no treatment were studied in parallel.
  2. 02HumanNon-randomized trialMechanism

    In men with prostate cancer, oestradiol fell by a mean of 46% from baseline after 6 months of goserelin.

    In plain wordsIn men with prostate cancer, oestradiol fell by 46% on average from baseline after 6 months of goserelin.

    Peptide
    Goserelin
    Outcome
    DecreaseOestradiol
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean change in oestradiol from baseline
    −46%
    goserelin, baseline to 6 months

    Source sentences

    Summary
    Mean changes in testosterone and oestradiol, respectively, from baseline to 6 months were -88% and -46% with goserelin, +50% and +44% with bicalutamide, and -1% and -9% for the 'no-treatment' group.
    1 context sentence
    Summary · context
    Forty-three men (mean age 70.7 +/- 6.2 years) with prostate cancer were randomized to goserelin (an LH-releasing hormone analogue) or bicalutamide (an androgen-receptor blocker) for 6 months; 20 men with a history of prostate cancer on no treatment were studied in parallel.
  3. 03HumanNon-randomized trialMechanism

    In men with prostate cancer, goserelin significantly increased median NT-proBNP from 66 to 87 ng/l at 3 months.

    In plain wordsIn men with prostate cancer, NT-proBNP increased from baseline after 3 months of goserelin.

    Peptide
    Goserelin
    Outcome
    IncreaseNT-proBNP at 3 months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 3 monthsAs given in this study (human).

    Measurements

    Median NT-proBNP
    66 ng/l
    goserelin, baseline
    Median NT-proBNP
    87 ng/l
    goserelin, 3 months

    Source sentences

    Summary
    Goserelin caused a significant increase from baseline to 3 months but not to 6 months (median value at baseline, 3 and 6 months: 66, 87 and 72 ng/l, respectively).
    1 context sentence
    Summary · context
    Forty-three men (mean age 70.7 +/- 6.2 years) with prostate cancer were randomized to goserelin (an LH-releasing hormone analogue) or bicalutamide (an androgen-receptor blocker) for 6 months; 20 men with a history of prostate cancer on no treatment were studied in parallel.
  4. 04HumanNon-randomized trialMechanism

    In men with prostate cancer, median NT-proBNP did not increase significantly with goserelin at 6 months: 66 ng/l at baseline and 72 ng/l.

    In plain wordsIn men with prostate cancer, NT-proBNP did not increase significantly from baseline after 6 months of goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeNT-proBNP at 6 months
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Median NT-proBNP
    66 ng/l
    goserelin, baseline
    Median NT-proBNP
    72 ng/l
    goserelin, 6 months

    Source sentences

    Summary
    Goserelin caused a significant increase from baseline to 3 months but not to 6 months (median value at baseline, 3 and 6 months: 66, 87 and 72 ng/l, respectively).
    1 context sentence
    Summary · context
    Forty-three men (mean age 70.7 +/- 6.2 years) with prostate cancer were randomized to goserelin (an LH-releasing hormone analogue) or bicalutamide (an androgen-receptor blocker) for 6 months; 20 men with a history of prostate cancer on no treatment were studied in parallel.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.